ARS Pharmaceuticals (SPRY) EBIT Growth (3y) (2023 - 2026)
ARS Pharmaceuticals (SPRY) EBIT Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 79.65% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | -47.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.58% |
| Dec 31, 2025 | -38.99% |
| Sep 30, 2025 | -100.19% |
| Jun 30, 2025 | -95.79% |
| Mar 31, 2025 | -73.66% |
| Dec 31, 2024 | 0.41% |
| Sep 30, 2024 | 1.39% |
| Jun 30, 2024 | 14.46% |
| Mar 31, 2024 | 11.27% |
| Dec 31, 2023 | 7.93% |
| Sep 30, 2023 | -30.38% |
| Jun 30, 2023 | -47.17% |
| Mar 31, 2023 | -52.83% |